keyword
MENU ▼
Read by QxMD icon Read
search

HIV treatment failure

keyword
https://www.readbyqxmd.com/read/28086929/early-virological-failure-and-hiv-drug-resistance-in-ugandan-adults-co-infected-with-tuberculosis
#1
Amrei von Braun, Christine Sekaggya-Wiltshire, Alexandra U Scherrer, Brian Magambo, Andrew Kambugu, Jan Fehr, Barbara Castelnuovo
PURPOSE: This cross-sectional study took place in the integrated tuberculosis (TB) clinic of a large outpatient clinic for HIV-infected patients in Kampala, Uganda. The purpose of this study was to describe the proportion of TB/HIV co-infected adults with virological failure, type and frequency of HIV drug resistance-associated mutations, and the proportion of patients with suboptimal efavirenz levels. METHODS: HIV-1 plasma viral loads, CD4 cell count measurements, and efavirenz serum concentrations were done in TB/HIV co-infected adults...
January 5, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28076335/infrequent-development-of-drug-resistance-in-hiv-1-infected-treatment-naive-subjects-after-96-weeks-of-treatment-with-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-or-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate
#2
Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D Miller, Christian Callebaut
BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide RT inhibitor (NtRTI) tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF). The single-tablet regimen (STR) composed of elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) has demonstrated non-inferiority to the STR of E/C/F/TDF in clinical studies, with high proportions of subjects achieving HIV-1 RNA <50 copies/mL at week 48, and maintained through week 96...
January 11, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28070174/the-hcv-treatment-revolution-continues-resistance-considerations-pangenotypic-efficacy-and-advances-in-challenging-populations
#3
Ira M Jacobson
The US Food and Drug Administration has now approved 10 direct-acting antivirals (DAAs) for the management of hepatitis C virus (HCV). These therapies are combined into 6 regimens that are given for varying durations, with or without ribavirin, depending on the viral genotype, the presence or absence of baseline resistance-associated variants (RAVs), and the patient type. RAVs may be present before exposure to a drug or may become detectable de novo during exposure to a drug. Emerging resistant strains are the most common cause of failure of HCV DAA regimens...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28067119/efficacy-and-safety-of-unboosting-atazanavir-in-a-randomized-controlled-trial-among-hiv-infected-patients-receiving-tenofovir-df
#4
Marianne Harris, Bruce Ganase, Birgit Watson, Mark W Hull, Silvia A Guillemi, Wendy Zhang, Ramesh Saeedi, P Richard Harrigan
OBJECTIVES: To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir disoproxil fumarate (TDF). METHODS: HIV-infected adults with viral load (VL) <40 copies/mL at screening and <150 copies/mL consistently for ≥3 months while receiving a regimen including ATV/r and TDF were randomized to continue ATV/r 300/100 mg daily (control) or change to ATV 400 mg daily (switch), while maintaining their TDF backbone...
January 9, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28063460/managing-two-decades-of-visceral-leishmaniasis-and-hiv-co-infection-a-case-report-that-illustrates-the-urgent-research-needs-in-the-field
#5
Melissa L Kelly, Angie N Pinto, Dan Suan, Debbie Marriott, David A Cooper, Sarah L Pett
Visceral leishmaniasis and HIV co-infection presents diagnostic, monitoring and treatment challenges. This is a report of a co-infected patient who developed multiple complications and treatment side-effects, including renal and liver failure, pancytopenia with recurrent sepsis, along with anal cancer, depression and poor quality-of-life spanning over two decades. Urgent research specific to this cohort is needed.
January 9, 2017: Sexual Health
https://www.readbyqxmd.com/read/28062146/intensive-statin-regimens-for-reducing-risk-of-cardiovascular-diseases-among-human-immunodeficiency-virus-infected-population-a-nation-wide-longitudinal-cohort-study-2000-2011
#6
Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, Chen-Yi Yang, Nai-Ying Ko
OBJECTIVE: This study evaluated the risk of cardiovascular diseases (CVD) in a statin-treated HIV-infected population and the effects of intensive statin regimens (i.e., high-dose or potency) on CVD risks. METHODS: 945 HIV-infected patients newly on statin treatment (144, 15.7% with CVD history) were identified from Taiwan's national HIV cohort. Using the median of the first year cumulative statin dosage as a cut-off point, patients were classified into either a high-dose or low-dose group...
December 21, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28061826/monophylogenetic-hiv-1c-epidemic-in-ethiopia-is-dominated-by-ccr5-tropic-viruses-an-analysis-of-a-prospective-country-wide-cohort
#7
Amare Worku Kalu, Nigus Fikrie Telele, Solomon Gebreselasie, Daniel Fekade, Samir Abdurahman, Gaetano Marrone, Anders Sönnerborg
BACKGROUND: CCR5 coreceptor using HIV-1 subtype C (HIV-1C) has been reported to dominate the Ethiopian epidemic. However, almost all data have been obtained from two large cities in the central and north-west regions and recent data is lacking. METHODS: Plasma were obtained from 420 treatment-naïve patients recruited 2009-2011 to a large country-wide Ethiopian cohort. The V3 region was sequenced and the co-receptor tropism was predicted by the clinical and clonal models of the geno2pheno tool at different false positive rates (fpr) and for subtype...
January 6, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28061753/treatment-efficacy-of-azithromycin-1%C3%A2-g-single-dose-versus-doxycycline-100%C3%A2-mg-twice-daily-for-7%C3%A2-days-for-the-treatment-of-rectal-chlamydia-among-men-who-have-sex-with-men-a-double-blind-randomised-controlled-trial-protocol
#8
Andrew Lau, Fabian Kong, Christopher K Fairley, Basil Donovan, Marcus Chen, Catriona Bradshaw, Mark Boyd, Janaki Amin, Peter Timms, Sepehr Tabrizi, David G Regan, David A Lewis, Anna McNulty, Jane S Hocking
BACKGROUND: Rectal infection with Chlamydia trachomatis is one of the most common bacterial sexually transmissible infections among men who have sex with men (MSM) with diagnosis rates continuing to rise. Current treatment guidelines recommend either azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days. However, there are increasing concerns about treatment failure with azithromycin. We are conducting the first randomised controlled trial (RCT) to compare treatment efficacy of azithromycin versus doxycycline for the treatment of rectal chlamydia in MSM...
January 6, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28052771/performance-based-financing-for-improving-hiv-aids-service-delivery-a-systematic-review
#9
Amitabh B Suthar, Jason M Nagata, Sabin Nsanzimana, Till Bärnighausen, Eyerusalem K Negussie, Meg C Doherty
BACKGROUND: Although domestic HIV/AIDS financing is increasing, international HIV/AIDS financing has plateaued. Providing incentives for the health system (i.e. performance-based financing [PBF]) may help countries achieve more with available resources. We systematically reviewed effects of PBF on HIV/AIDS service delivery to inform WHO guidelines. METHODS: PubMed, WHO Index Medicus, conference databases, and clinical trial registries were searched in April 2015 for randomised trials, comparative contemporaneous studies, or time-series studies...
January 4, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28049602/are-there-hiv-specific-differences-for-anal-cancer-patients-treated-with-standard-chemoradiotherapy-in-the-era-of-combined-antiretroviral-therapy
#10
D Martin, P Balermpas, E Fokas, C Rödel, M Yildirim
AIMS: Contradicting evidence exists regarding the safety and clinical outcome of standard treatment in HIV-positive patients with anal cancer. We report on our large, single-centre experience in HIV-positive versus HIV-negative patients treated in the era of combined antiretroviral therapy (CART). MATERIALS AND METHODS: Between 1997 and 2015, 142 patients (42 HIV-positive versus 100 HIV-negative) with anal cancer were treated with standard chemoradiotherapy. Patients received a median dose of 50...
December 31, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28043602/screening-new-tuberculosis-patients-in-mali-for-rifampicin-resistance-at-2months
#11
Bassirou Diarra, Aissata B Cissé, Ousmane Kodio, Moumine Sanogo, Bocar Baya, Antieme C G Togo, Amadou Somboro, Mohamed Tolofoudié, Boureima Degoga, Marie Laure Keita, Fatimata Diallo, Natacha Nguiakam, Gagni Coulibaly, Sidy Bane, Yeya Dit Sadio Sarro, Seydou Doumbia, Robert Leo Murphy, Souleymane Diallo, Bouke C Dejong
OBJECTIVE/BACKGROUND: The recent call for universal drug susceptibility testing (DST) for all tuberculosis (TB) patients will be difficult to meet in settings where Xpert rollout is limited, such as low prevalence of HIV and Multi-drug Resistant Tuberculosis (MDR) settings. As recommended by World Health Organization (WHO) guidelines, the success of TB treatment is measured by Ziehl-Neelsen (ZN) microscopy or auramine-rhodamine fluorescent microscopy (FM) on sputum, in which conversion to negative smear at 2months (M) is an important predictor of treatment success, defined as a negative smear at 5M...
December 2016: International Journal of Mycobacteriology
https://www.readbyqxmd.com/read/28043578/using-competing-risks-model-and-competing-events-in-outcome-of-pulmonary-tuberculosis-patients
#12
Mehdi Kazempour Dizaji, Anoshirvan Kazemnejad, Payam Tabarsi, Farid Zayeri
INTRODUCTION: Although tuberculosis (TB) is curable, the rate of failure and mortality is high in comparison to other infectious diseases worldwide. It has been shown that majority of TB patients leave treatment before completing the therapeutic regimen. The aftermath of incomplete regimens might result in drug resistant-TB bacilli (DR-TB), relapses, and death. For this reason, proper knowledge about the disease and associated risk factor is crucial to decreasing TB cases among the general population...
December 2016: International Journal of Mycobacteriology
https://www.readbyqxmd.com/read/28043527/overview-of-drug-resistant-tuberculosis-worldwide
#13
Ali A Velayati, Parissa Farnia, Amir M Farahbod
Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In 2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million people died. This is the real situation despite the well-structured treatment programs and availability of effective treatment options since the 1950s. The high mortality rate has been associated with other risk factors, such as the HIV epidemic, underlying diseases, and decline of socioeconomic standards. Furthermore, the problem of drug resistance that was recognized in the early days of the chemotherapeutic era raises serious concerns...
December 2016: International Journal of Mycobacteriology
https://www.readbyqxmd.com/read/28043170/impact-of-disease-drug-and-patient-adherence-on-the-effectiveness-of-antiviral-therapy-in-pediatric-hiv
#14
Chiara Piana, Meindert Danhof, Oscar Della Pasqua
Maintaining effective antiretroviral treatment for life is a major problem, in both resource-limited and resource-rich countries. Despite the progress observed in paediatric antiretroviral therapy, approximately 12% of children still experience treatment failure due to drug resistance, inadequate dosing and poor adherence. We explore the current status of antiretroviral therapy in children with focus on the interaction between disease, drug pharmacokinetics and patient behavior, all of which are strongly interconnected and determine treatment outcome...
January 3, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28042101/efavirenz-dissolution-enhancement-iii-colloid-milling-pharmacokinetics-and-electronic-tongue-evaluation
#15
Cristiane R D Hoffmeister, Cinira Fandaruff, Maíra A da Costa, Lucio M Cabral, Luciana R Pitta, Stanley E R Bilatto, Livia D Prado, Daniel S Corrêa, Leandro Tasso, Marcos Antônio S Silva, Helvécio V A Rocha
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is part of first-line therapy for the treatment of human immunodeficiency virus type 1 infection (HIV-1/AIDS). This drug shows relatively low oral absorption and bioavailability, as well as high intra- and inter-subject variability. Several studies have shown that treatment failure and adverse effects are associated with low and high EFV plasma concentrations, respectively. Some studies suggest different EFV formulations to minimize inter-patient variability and improve its solubility and dissolution; however, all of these formulations are complex, using for instance, cyclodextrins, dendrimers and polymeric nanoparticles, rendering them inviable industrially...
December 29, 2016: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28035758/genotypic-tropism-testing-of-proviral-dna-to-guide-maraviroc-initiation-in-aviraemic-subjects-48-week-analysis-of-results-from-the-protest-study
#16
E Poveda, J Hernández-Quero, M J Pérez-Elías, M A Ribas, O J Martínez-Madrid, J Flores, J Navarro, F Gutiérrez, M García-Deltoro, A Imaz, A Ocampo, A Artero, F Blanco, E Bernal, J Pasquau, C Mínguez-Gallego, N Pérez, A Aiestaran, F García, R Paredes
OBJECTIVES: Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. METHODS: PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with HIV-1 RNA < 50 copies/mL on stable ART during the previous 6 months who required an ART change because of toxicity and who had R5 HIV, as determined by proviral DNA genotypic tropism testing, initiated MVC with two nucleoside reverse transcriptase inhibitors (NRTIs) and were followed for 48 weeks...
December 30, 2016: HIV Medicine
https://www.readbyqxmd.com/read/28030621/hiv-clinical-pathway-a-new-approach-to-combine-guidelines-and-sustainability-of-anti-retroviral-treatment-in-italy
#17
Davide Croce, Adriano Lazzarin, Giuliano Rizzardini, Nicola Gianotti, Francesca Scolari, Emanuela Foglia, Elisabetta Garagiola, Elena Ricci, Teresa Bini, Tiziana Quirino, Paolo Viganò, Tiziana Re, Antonella D'Arminio Monforte, Paolo Bonfanti
The present article describes the case study of a "real world" HIV practice within the debate concerning the strategic role of Clinical Governance (CG) tools in the management of a National Healthcare System's sustainability. The study aimed at assessing the impact of a Clinical Pathway (CP) implementation, required by the Regional Healthcare Service, in terms of effectiveness (virological and immunological conditions) and efficiency (economic resources absorption), from the budget holder perspective. Data derived from a multi-centre cohort of patients treated in 6 Hospitals that provided care to approximately 42% of the total HIV+ patients, in Lombardy Region, Italy...
2016: PloS One
https://www.readbyqxmd.com/read/28030600/isoniazid-mono-resistant-tuberculosis-impact-on-treatment-outcome-and-survival-of-pulmonary-tuberculosis-patients-in-southern-mexico-1995-2010
#18
Renata Báez-Saldaña, Guadalupe Delgado-Sánchez, Lourdes García-García, Luis Pablo Cruz-Hervert, Marlene Montesinos-Castillo, Leticia Ferreyra-Reyes, Miriam Bobadilla-Del-Valle, Sergio Canizales-Quintero, Elizabeth Ferreira-Guerrero, Norma Téllez-Vázquez, Rogelio Montero-Campos, Mercedes Yanes-Lane, Norma Mongua-Rodriguez, Rosa Areli Martínez-Gamboa, José Sifuentes-Osornio, Alfredo Ponce-de-León
BACKGROUND: Isoniazid mono-resistance (IMR) is the most common form of mono-resistance; its world prevalence is estimated to range between 0.0 to 9.5% globally. There is no consensus on how these patients should be treated. OBJECTIVE: To describe the impact of IMR tuberculosis (TB) on treatment outcome and survival among pulmonary TB patients treated under programmatic conditions in Orizaba, Veracruz, Mexico. MATERIALS AND METHODS: We conducted a prospective cohort study of pulmonary TB patients in Southern Mexico...
2016: PloS One
https://www.readbyqxmd.com/read/28018346/low-double-negative-cd3-cd4-cd8-t-cells-are-associated-with-incomplete-restoration-of-cd4-t-cells-and-higher-immune-activation-in-hiv-1-immunological-non-responders
#19
Xiaofan Lu, Bin Su, Huan Xia, Xin Zhang, Zhiying Liu, Yunxia Ji, Zixuan Yang, Lili Dai, Luzia M Mayr, Christiane Moog, Hao Wu, Xiaojie Huang, Tong Zhang
Failure of immune reconstitution increases the risk of AIDS or non-AIDS related morbidity and mortality in HIV-1-infected patients. CD3(+)CD4(-)CD8(-) T cells, which are usually described as double-negative (DN) T cells, display CD4-like helper and immunoregulatory functions. Here, we have measured the percentage of DN T cells in the immune reconstituted vs. non-immune reconstituted HIV-1-infected individuals. We observed that immunological non-responders (INRs) had a low number of DN T cells after long-term antiretroviral therapy (ART), and the number of these cells positively correlated with the CD4(+) T cell count...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/28002185/field-evaluation-of-dried-blood-spots-for-hiv-1-viral-load-monitoring-in-adults-and-children-receiving-antiretroviral-treatment-in-kenya-implications-for-scale-up-in-resource-limited-settings
#20
Mary E Schmitz, Simon Agolory, Muthoni Junghae, Laura N Broyles, Muthusi Kimeu, Joseph Ombayo, Mamo Umuro, Irene Mukui, Kennedy Alwenya, Moses Baraza, Kenneth Ndiege, Samuel Mwalili, Emilia Rivadeneira, Lucy Ng'ang'a, Chunfu Yang, Clement Zeh
BACKGROUND: WHO recommends viral load (VL) as the preferred method for diagnosing antiretroviral therapy (ART) failure; however, operational challenges have hampered the implementation of VL monitoring in most resource-limited settings. This study evaluated the accuracy of dried blood spot (DBS) VL testing under field conditions as a practical alternative to plasma in determining virologic failure (VF). METHODS: From May to December 2013, paired plasma and DBS specimens were collected from 416 adults and 377 children on ART ≥6 months at 12 clinics in Kenya...
December 17, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
keyword
keyword
66741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"